Use of GLP-2 and related compounds for the treatment,...

Details Use of GLP-2 and related compounds for the treatment,... Use of GLP-2 and related compounds for the treatment,...

2008-05-13

2008-05-13

Gupta, Anish (Department: 1654)

Drug, bio-affecting and body treating compositions

Designated organic active ingredient containing

Peptide containing doai

C514S012200, C514S021800, C530S308000, C530S324000

Reexamination Certificate

active

11035826

ABSTRACT:
The present invention relates to methods for prevention and treatment of bone-related disorders and calcium homeostasis related syndromes using a GLP-2 molecule or GLP-2 activator either alone or in combination with another therapeutic. The present invention also encompasses methods of diagnosing or monitoring the progression of a disorder. The invention also encompasses methods of monitoring the effectiveness of treatment of the invention.

REFERENCES:
patent: 5317010 (1994-05-01), Pang et al.
patent: 5556940 (1996-09-01), Willick et al.
patent: 5789379 (1998-08-01), Drucker et al.
patent: 5834428 (1998-11-01), Drucker
patent: 5912229 (1999-06-01), Thim et al.
patent: 5952301 (1999-09-01), Drucker
patent: 5990077 (1999-11-01), Drucker
patent: 5994500 (1999-11-01), Drucker et al.
patent: 6037143 (2000-03-01), Wagner et al.
patent: 6048524 (2000-04-01), Selden et al.
patent: 6051557 (2000-04-01), Drucker
patent: 6077949 (2000-06-01), Munroe et al.
patent: 6110949 (2000-08-01), Villhauer
patent: 6166063 (2000-12-01), Villhauer
patent: 6184201 (2001-02-01), Drucker et al.
patent: 6770620 (2004-08-01), Henriksen
patent: 6943151 (2005-09-01), Henriksen et al.
patent: 7001911 (2006-02-01), Salvati et al.
patent: 7186683 (2007-03-01), Henriksen et al.
patent: 2004/0082507 (2004-04-01), Henriksen et al.
patent: 0 955 314 (1999-10-01), None
patent: WO-96/32414 (1996-10-01), None
patent: WO-97/31943 (1997-09-01), None
patent: WO-97/39031 (1997-10-01), None
patent: WO-98/01535 (1998-01-01), None
patent: WO-98/03547 (1998-01-01), None
patent: WO-98/08872 (1998-03-01), None
patent: WO-98/24813 (1998-06-01), None
patent: WO-98/25644 (1998-06-01), None
patent: WO-98/25955 (1998-06-01), None
patent: WO-98/52600 (1998-11-01), None
patent: WO-99/06059 (1999-02-01), None
patent: WO-99/14239 (1999-03-01), None
patent: WO-99/37793 (1999-07-01), None
patent: WO-99/38501 (1999-08-01), None
patent: WO-99/43361 (1999-09-01), None
patent: WO-99/46283 (1999-09-01), None
patent: WO-99/58144 (1999-11-01), None
patent: WO-00/10549 (2000-03-01), None
patent: WO-00/18371 (2000-04-01), None
patent: WO-00/20592 (2000-04-01), None
patent: WO-00/34331 (2000-06-01), None
patent: WO-00/34332 (2000-06-01), None
patent: WO-00/37053 (2000-06-01), None
patent: WO-00/42026 (2000-07-01), None
patent: WO-00/53208 (2000-09-01), None
patent: WO-01/04156 (2001-01-01), None
patent: WO-01/41779 (2001-06-01), None
patent: WO-01/87332 (2001-11-01), None
patent: WO-01/98331 (2001-12-01), None
patent: WO-02/10195 (2002-02-01), None
patent: WO-02/24214 (2002-03-01), None
patent: WO-02/066062 (2002-08-01), None
Francis, Roger M., “Bisphosphonates in the Treatment of osteoporosis in 1997: A Review”; Current Therapeutic Research, vol. 58, pp. 656-678, No. 10, Oct. 1997.
Haderslev, K.V. et al., “Short-term Administration of Gluagon-like Peptide-2. Effects on Bone Mineral Density and Markers of Bone Turnover in Short-Bowel Patients with No Colon”; Taylor & Francis Healthsciences, pp. 392-398.
Andreasen et al., 1994, “Secretion of glucagon-like-peptide-1 and reactive hypoglycemia after partial gastrectomy”, Digestion 55:221-228.
Bell et al., 1983, “Exon duplication and divergence in the human preproglucagon gene”, Nature 304:368-371.
Buhl et al., 1988, “Naturally occurring products of proglucagon 111-160 in the porcine and human small intestine.” J. Biol. Chem. 263:8621-8624.
Cheeseman and Tseng, 1996, “The effect of GIP and glucagon-like peptides on intestinal basolateral membrane hexose transport”. Am. J. Physiol. 271:G477-G482.
Drucker et al., 1996 “Induction of intestinal epithelial proliferation by glucagon-like peptide 2” Proc. Natl. Acad. Sci. USA 93:7911-7916.
Graham and Malaty, 1999, “Alendronate gastric ulcers”, Aliment Pharmacol. Ther. 13:515-519.
Hartman et al., 2000, “In vivo and in vitro degradation of glucagon-like peptide 2 in humans”, J. Clin. Endocrinol. Metab. 85:2884-2888.
Irwin and Wong, 1995, “Trout and chicken proglucagon: alternative splicing generates mRNA transcripts encoding lucagon-like peptide 2”, Mol. Endocrinol. 9:267-277.
Jelinek et al., 1993, “Expression cloning and signaling properties of the rat glucagon receptor”, Science 259:1614-1616.
Jeppesen et al., 2000, “Elevated plasma glucagon-like peptide 1 and 2 concentrations in ileum resected shor bowel patients with a preserved colon”, Gut 47:370-376.
Mojsov, 1992, “Structural requirements for biological activity of glucagon-like peptide-1”, Intl. J. Pep. Prot. Res. 40:333-343.
Munroe et al., 1999, Prototypic G protein-coupled receptor for the intestinotrophic factor glucagon-like peptide 2, Proc. Natl. Acad. Sci. USA 96:1569-1573.
Nishi and Steiner, 1990, “Cloning and complementary DNAs encoding islet amyloid polypeptide, insulin, and glucagon precursors from a New World rodent, the degu,Octodon degu”, Mol. Endocrinol. 4:1192-1198.
Persson et al., 1997, “Hormone replacement therapy and the risk of breast cancer. Nested case-control study in a cohort of Swedish women attending mammography screening”, Intl. J. Can. 72:758-761.
Rosenquist et al., 1998, “Serum CrossLaps ONe Step ELISA. First application of monclonal antibodies for measurement in serum of bone-related degradation products from C-terminal telopeptides of type 1 collagen”, Clin. Chem. 44:-2281-2289.
Schlemmer and Hassager, 1999, “Acute fasting diminishes the circadian rhythm of biochemical markers of bone resorption”, Eur. J. Endocrinol. 140:332-337.
Schlemmer et al., 1994, Posture, age, menopause and osteopenia do not influence the circadian variation in the urinary excretion of pyridinium crosslinks:, J. Bone Mineral Res. 9:1883-1888.
Thorens, 1992 “Expression cloning of pancreatic cell receptor for the gluco-incretin hormone glucagon-like peptide 1” Proc. Natl. Acad. Sci USA 89:8641-8645.
Unger and Orci, eds., 1981, “Glucagon. Physiology, Pathophysiology and Morphology of the Pancreatic A-Cells”, New York, Elsevier, pp. 140-120.

Affiliated with

Also associated with

Rating

Use of GLP-2 and related compounds for the treatment,... does not yet have a rating. At this time, there are no reviews or comments for this patent.

If you have personal experience with Use of GLP-2 and related compounds for the treatment,..., we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Use of GLP-2 and related compounds for the treatment,... will most certainly appreciate the feedback.

Rate now

Comments { 0 }

Profile ID: LFUS-PAI-O-3941557